COMPOSITION:
Vildana D 50/5
Each film-coated tablet contains
Vildagliptin SR 100 mg + Dapagliflozin 5 mg
Vildana D 100/10
Each film-coated tablet contains
Vildagliptin SR 100 mg + Dapagliflozin 10 mg
SUMMARY:
The glucagon-like peptide-1 (GLP-1) is secreted from the alimentary canal, in response to a meal. This promotes insulin secretion from the pancreas and regulates blood glucose post-meal by controlling glucagon secretion. Vildagliptin exhibits a hypoglycemic effect by controlling the degradation of GLP-1 by inhibiting dipeptidyl peptidase-4 (DPP-4) activity. Thus, increases the blood concentration of active GLP-1.
Category: DPP4 Inhibitors
Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion.
Category: SGLT2 Inhibitors
Mechanism of Action:
By increasing the endogenous levels of these incretin hormones, Vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Treatment with Vildagliptin 50- 100 mg daily in patients with type 2 diabetes significantly improved markers of beta-cell function including HOMA-ß (Homeostasis Model Assessment–ß), proinsulin to insulin ratio, and measures of beta-cell responsiveness from the frequently-sampled meal tolerance test. In non-diabetic (normal glycaemic) individuals, Vildagliptin does not stimulate insulin secretion or reduce glucose levels
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increasing urinary glucose excretion.
Indications:
Vildana D is a dipeptidyl peptidase-4 (DPP-4) inhibitor and SGLT-2 inhibitor combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Vildagliptin and Dapagliflozin is appropriate
Side Effects:
Patients undergoing treatment with Vildana D may experience side effects, such as: Nausea, Eczema, Constipation, Pain in the abdomen & accumulation of gas in the gastrointestinal tract, diarrhea, cough or hoarseness, breathing problems, coma, and confusion.
Contraindications:
Any patient with a known hypersensitivity to Vildagliptin or any of the components in the formulation, Severe ketosis, diabetic coma or history of diabetic coma, type 1 diabetic patients, Patients with severe infection, surgery, severe trauma (blood sugar control should preferably be done by insulin).
Patients with a history of serious hypersensitivity reaction to Dapagliflozin. Severe renal impairment, end-stage renal disease, or dialysis.
DISCLAIMER: All content published online is for informational purposes only. It is not intended to be a substitute for professional medical advice. Always seek the guidance of your doctor with any questions you may have regarding your health, medical condition, or any medicines.